Brought to you by 
Catabasis, Sarepta ally in combo therapy for DMD
18 May 2017
Executive Summary
Catabasis Pharmaceuticals Inc. and Sarepta Therapeutics Inc. will jointly collaborate on a combination drug treatment for Duchenne muscular dystrophy (DMD), a rare and fatal genetic disease caused by a mutation in the dystrophin gene, a protein essential to muscle function.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Catabasis, Sarepta ally in combo therapy for DMD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice